TvI - jaargang 12, nummer 2, april 2017
dr. M.T.D. Weiland , dr. P. Kuijer , dr. J.W. Mulder , dr. F.N. Lauw , dr. J.M.M. Otten
Reactivatie van hepatitis B kan voorkomen bij oncologische patiënten die worden blootgesteld aan immunosuppressieve therapie. In dit artikel wordt casuïstiek met deze complicatie beschreven evenals valkuilen en adviezen wat betreft screening, follow-up en behandeling.
(TIJDSCHR INFECT 2017;12(2):46-52)
Lees verder
Naar boven
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
